Avidity Partners Management’s Legend Biotech LEGN Stock Holding History

Avidity Partners Management’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$433K	Buy	+15,000	New	+$405K	0.07%	42
2024 Q3	–	Sell	-398,000	Closed	-$17.6M	–	92
2024 Q2	$17.6M	Sell	398,000 -270,300	-40%	-$12.5M	0.75%	49
2024 Q1	$37.5M	Sell	668,300 -16,700	-2%	-$1.01M	1.21%	30
2023 Q4	$41.2M	Sell	685,000 -282,000	-29%	-$17.9M	1.5%	30
2023 Q3	$65M	Buy	967,000 +168,100	+21%	+$11.7M	2.62%	6
2023 Q2	$55.1M	Sell	798,900 -321,600	-29%	-$21M	1.93%	19
2023 Q1	$54M	Buy	1,120,500 +150,500	+16%	+$7.36M	1.79%	21
2022 Q4	$48.4M	Buy	+970,000	New	+$47M	1.05%	32
2022 Q3	–	Sell	-1,000,000	Closed	-$55M	–	101
2022 Q2	$55M	Sell	1,000,000 -95,000	-9%	-$4.01M	1.26%	26
2022 Q1	$39.8M	Buy	1,095,000 +383,100	+54%	+$15.1M	0.83%	35
2021 Q4	$33.2M	Sell	711,900 -182,100	-20%	-$9.24M	0.7%	45
2021 Q3	$45.2M	Buy	894,000 +269,000	+43%	+$11.2M	1%	32
2021 Q2	$25.7M	Buy	+625,000	New	+$21.2M	0.69%	46
2020 Q3	–	Sell	-100,000	Closed	-$4.26M	–	78
2020 Q2	$4.26M	Buy	+100,000	New	+$3.91M	0.27%	53

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Avidity Partners Management's LEGN Position: Q2 2026 in Review

Avidity Partners Management opened a new position in Legend Biotech (LEGN) in Q2 2026: 15,000 shares worth $433K. The stake represents 0.07% of the portfolio and ranks #42 among its holdings. This is a return to the name: Avidity Partners Management previously reported a position in LEGN as recently as Q2 2024.

Avidity Partners Management first reported a position in LEGN in Q2 2020 and has held it in 14 quarters since. The position peaked at $65M in Q3 2023. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Avidity Partners Management held 15,000 shares of Legend Biotech worth $433K as of Q2 2026.
Legend Biotech was a new Avidity Partners Management position in Q2 2026.
Legend Biotech made up 0.07% of Avidity Partners Management's portfolio in Q2 2026, its #42 holding.
Avidity Partners Management first reported a position in Legend Biotech in Q2 2020 and has held it in 14 quarters since.
Avidity Partners Management's Legend Biotech position peaked at $65M in Q3 2023.
218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.